Li Guiyin, He Wei, Yan Ruijie, Cen Cunhong, Tan Xiaohong, He Yanhong, Wu Dang, Huang Yong
College of Chemistry, School of Materials Science and Engineering, Guangdong University of Petrochemical Technology, Maoming, 525000, Guangdong, People's Republic of China; State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, 530021, People's Republic of China.
College of Chemistry, School of Materials Science and Engineering, Guangdong University of Petrochemical Technology, Maoming, 525000, Guangdong, People's Republic of China.
Talanta. 2025 Nov 1;294:128279. doi: 10.1016/j.talanta.2025.128279. Epub 2025 May 5.
Hepatocellular carcinoma (HCC), characterized by poor early diagnosis, exhibits the second-highest lethality rate among malignancies. This clinical challenge underscores the significance of Golgi protein 73 (GP73) as a promising serum biomarker for HCC detection. Herein, a ratiometric fluorescent aptasensor was constructed employing a dual-signal modulation strategy. The system integrated boron, nitrogen co-doped carbon quantum dots (BNCQDs) as the first fluorescent signal (I) with a functional copper-based metalorganic framework conjugated with GP73-specific aptamer (Cu-MOF-Apt). The latter served dual functions: target recognition and peroxidase-mimetic catalyst for converting o-phenylenediamine (OPD) to 2,3-diaminophenazine (DAP), another fluorescent signal (I). The peroxidase-like activity of Cu-MOF increased with the increase of GP73 attached. In the presence of GP73, target binding induced structural disintegration of Cu-MOF-Apt through GP73-Apt complex formation, thereby suppressing DAP generation. This target-responsive process led to the reduction of the fluorescence intensity of DAP and the increase of the fluorescence intensity of BNCQDs. Under the optimal conditions, the established ratiometric relationship (I/I = 0.0007X + 0.7021, R = 0.997) enables quantitative detection of GP73 in the range of 25.00-600.00 ng/mL with the limit of detection (LOD) of 14.06 ng/mL. Clinical validation using serum specimens demonstrated excellent reproducibility (RSD 0.28 %-0.98 %) and recovery rates (99.75 %-107.49 %). The ratiometric fluorescent aptasensor's linear range effectively covers clinically relevant GP73 concentrations in HCC patients, while the robust serum analysis performance confirms its potential for practical diagnostic applications.
肝细胞癌(HCC)早期诊断困难,在恶性肿瘤中致死率位居第二。这一临床挑战凸显了高尔基体蛋白73(GP73)作为一种有前景的HCC检测血清生物标志物的重要性。在此,采用双信号调制策略构建了一种比率荧光适配体传感器。该系统将硼、氮共掺杂碳量子点(BNCQDs)作为第一荧光信号(I)与结合了GP73特异性适配体的功能性铜基金属有机框架(Cu-MOF-Apt)相结合。后者具有双重功能:靶标识别以及作为过氧化物酶模拟催化剂将邻苯二胺(OPD)转化为另一种荧光信号(I)2,3 - 二氨基吩嗪(DAP)。Cu-MOF的过氧化物酶样活性随着附着的GP73增加而增强。在存在GP73的情况下,靶标结合通过形成GP73 - 适配体复合物诱导Cu-MOF-Apt的结构解体,从而抑制DAP的产生。这个靶标响应过程导致DAP荧光强度降低以及BNCQDs荧光强度增加。在最佳条件下,建立的比率关系(I/I = 0.0007X + 0.7021,R = 0.997)能够在25.00 - 600.00 ng/mL范围内定量检测GP73,检测限(LOD)为14.06 ng/mL。使用血清样本进行的临床验证显示出优异的重现性(RSD 0.28% - 0.98%)和回收率(99.75% - 107.49%)。比率荧光适配体传感器的线性范围有效覆盖了HCC患者临床相关GP73浓度,同时强大的血清分析性能证实了其在实际诊断应用中的潜力。